HAYWARD, Calif.–(BUSINESS WIRE)– The National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), awarded Aradigm Corporation (ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into … Continue reading →

Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even … Continue reading →

On Monday, July 29, 2013, leading lung disease researchers from around the globe will participate in the fifth biennial “Stem Cells and Cell Therapies in Lung Biology Conference” at the University of Vermont (UVM). Since the meeting’s initiation eight years … Continue reading →

Compugen Ltd. (NASDAQ: CGEN [FREE Stock Trend Analysis]) announced today that the company has received an Issue Notification from the U.S. Patent and Trademark Office for a patent application covering the company’s drug candidate CGEN-25009. CGEN-25009 is intended for the … Continue reading →

LAVAL, QUEBEC–(Marketwired – July 11, 2013) – ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), (“ProMetic” or the “Corporation”) announced today that its lead drug candidate PBI-4050, is on track to enter the clinical trial program starting in September 2013. During the … Continue reading →

The first person to get a double lung transplant at the University of Washington is still breathing strong 20 years later. Ken Price had been living with cystic fibrosis since he was 1 year old, KOMO-TV reports. He was the … Continue reading →

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients. The study also found that certain proteins found in lung fluid can help predict whether a patient’s … Continue reading →

Summary Background Abnormal acid gastro-oesophageal reflux is common in patients with idiopathic pulmonary fibrosis (IPF) and is considered a risk factor for development of IPF. Retrospective studies have shown improved outcomes in patients given anti-acid treatment. The aim of this … Continue reading →